Agios Pharmaceuticals, Inc.(AGIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AGIO Agios Pharmaceuticals, Inc.

休市中 07-31 16:00:00 EDT

30.02

-2.73

-8.34%

盘后29.97

-0.05-0.17%

19:34 EDT

最高33.34	最低29.94	成交量210.21万
今开33.34	昨收32.75	日振幅10.38%
总市值17.85亿	流通市值15.03亿	总股本5,947万
成交额6,501万	换手率4.20%	流通股本5,006万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AGIO","market":"US","secType":"STK","nameCN":"Agios Pharmaceuticals, Inc.","latestPrice":30.02,"timestamp":1785528000000,"preClose":32.75,"halted":0,"volume":2102051,"hourTrading":{"tag":"盘后","latestPrice":29.97,"preClose":30.02,"latestTime":"19:34 EDT","volume":2736,"amount":82012.7262,"timestamp":1785540848175,"change":-0.05,"changeRate":-0.001666,"amplitude":0.007032},"delay":0,"changeRate":-0.08335877862595421,"floatShares":50063000,"shares":59471609,"eps":-7.255931,"marketStatus":"休市中","change":-2.73,"latestTime":"07-31 16:00:00 EDT","open":33.34,"high":33.34,"low":29.94,"amount":65006467.402107,"amplitude":0.103817,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.255931,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1374638400000,"exchange":"NASDAQ","adjPreClose":32.75,"postHourTrading":{"tag":"盘后","latestPrice":29.97,"preClose":30.02,"latestTime":"19:34 EDT","volume":2736,"amount":82012.7262,"timestamp":1785540848175,"change":-0.05,"changeRate":-0.001666,"amplitude":0.007032},"volumeRatio":1.4998845501582954,"impliedVol":0.7372,"impliedVolPercentile":0.8008},"requestUrl":"/m/hq/s/AGIO/wiki","defaultTab":"wiki","newsList":[{"id":"1130331722","title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计大幅增长，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1130331722","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130331722?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:55","pubTimestamp":1784840149,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc.将于2026年07月30日发布最新季度财报，市场聚焦收入增长与亏损收窄的节奏及关键产品商业化执行。市场一致预期显示，本季度Agios Pharmaceuticals, Inc.营收预计为2,552.12万美元，同比增长169.23%；调整后每股收益预计为-1.67美元，同比改善7.72%；息税前利润预计为-1.11亿美元，同比改善6.20%。上季度Agios Pharmaceuticals, Inc.营收2,074.60万美元，同比增长137.75%；毛利率-297.51%；归属母公司净利润为-9,911.10万美元，净利率数据未披露；调整后每股收益为-1.69美元，同比改善9.03%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计大幅增长，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146580463","title":"Agios Pharmaceuticals 终止镰状细胞病药物研发 盘前股价重挫12.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146580463","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146580463?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:07","pubTimestamp":1784632035,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc. 宣布终止其镰状细胞病药物的研发项目，这一决定令市场感到意外，并立即在股价上引发剧烈反应。消息公布后，该公司股价在盘前交易时段应声下跌12.6%。\n这一战略调整意味着公司放弃了在该治疗领域的重大投入，将资源重新配置至其他研发管线。市场普遍认为，此次研发终止对公司的短期前景构成压力，并可能影响投资者对其长期增长潜力的评估。目前，市场正密切关注Agios Pharmaceuticals 后续的研发策略与业务重心转移。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142456730","title":"Agios Pharmaceuticals - FDA授予Mitapivat用于镰状细胞病的优先审评资格；PDUFA日期定于2026年11月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=1142456730","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142456730?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:01","pubTimestamp":1784631697,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc. 宣布，美国食品药品监督管理局（FDA）已接受其药物Mitapivat用于治疗镰状细胞病的新药申请，并授予其优先审评资格。该申请的PDUFA目标日期定为2026年11月1日。这一进展标志着该药物在应对这一严重血液疾病方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197120724","title":"Agios Pharmaceuticals公司Tebapivat治疗组主要终点达成率高达47.1%；安慰剂组为33.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197120724","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197120724?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:01","pubTimestamp":1784631685,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals公司（AGIO）宣布，其药物Tebapivat在临床试验中取得了积极结果。数据显示，接受Tebapivat治疗的患者组中，达到主要终点的比例最高可达47.1%。相比之下，安慰剂对照组的这一比例则为33.3%。这一结果凸显了该试验性疗法的潜在疗效优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153484354","title":"Agios Pharmaceuticals股价飙升12.4% 美国FDA授予其镰状细胞病药物优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1153484354","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153484354?lang=zh_cn&edition=full","pubTime":"2026-07-07 22:37","pubTimestamp":1783435046,"startTime":"0","endTime":"0","summary":"在获得美国食品药品监督管理局（FDA）对其镰状细胞病治疗药物授予优先审评资格后，Agios Pharmaceuticals, Inc.的股价应声大涨12.4%。这一关键监管进展显著缩短了药物的审评时间表，为潜在加速上市铺平道路，从而激发了市场的积极反应。公司股价的强劲上扬，反映出投资者对这款创新疗法商业前景的信心增强，以及对公司研发管线价值的重估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149898833","title":"Agios在EHA 2026全体会议上公布RISE UP三期试验结果，强化米塔匹韦在镰状细胞病中的强大抗溶血特性","url":"https://stock-news.laohu8.com/highlight/detail?id=1149898833","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149898833?lang=zh_cn&edition=full","pubTime":"2026-06-13 21:00","pubTimestamp":1781355620,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc. (AGIO) 在2026年欧洲血液学协会全体会议上，隆重展示了其关键性RISE UP三期临床试验的完整数据。这些结果有力地证实了其研究药物米塔匹韦在治疗镰状细胞病患者时，展现出卓越且持久的抗溶血疗效。\n此次公布的数据进一步强化了米塔匹韦的临床价值。分析显示，该药物能显著降低患者的溶血标志物水平，改善贫血状况，并展现出良好的安全性与耐受性。这一积极成果为米塔匹韦作为潜在的新型疗法，满足镰状细胞病领域迫切的医疗需求，提供了坚实的证据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130178478","title":"Agios Pharmaceuticals与Oscotec达成协议：预付2500万美元及里程碑付款与分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1130178478","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130178478?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:03","pubTimestamp":1780304633,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc.与Oscotec公司已达成一项合作协议，根据协议，Oscotec将获得高达2500万美元的预付费用。此外，该协议还包括基于未来研发和商业化进展的里程碑付款，以及根据销售额分层的特许权使用费安排。这一合作旨在推动特定治疗领域的创新药物开发，进一步强化Agios Pharmaceuticals在生物医药领域的战略布局。财务条款的细节突显了双方对项目潜力的共同信心，同时也为Agios Pharmaceuticals的未来收入流增添了多样性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106333345","title":"Agios与Oscotec达成独家全球授权协议，共同开发并商业化新一代Syk抑制剂Cevidoplenib","url":"https://stock-news.laohu8.com/highlight/detail?id=1106333345","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106333345?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:00","pubTimestamp":1780304424,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals（简称Agios）已同Oscotec签署了一项独家全球授权协议，双方将携手推进新一代脾酪氨酸激酶抑制剂Cevidoplenib的开发与商业化进程。这一合作标志着两家公司在创新疗法领域迈出了重要一步，旨在加速该候选药物的全球研发与市场布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172599386","title":"Agios Pharmaceuticals宣布停止血液病药物研发，盘前股价暴跌19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172599386","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172599386?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:08","pubTimestamp":1780052918,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc. (AGIO) 盘前交易时段股价重挫19%，此前该公司宣布将停止其一款血液病药物的后续开发工作。这一决定源于对研发项目战略价值的重新评估，标志着该公司研发管线的一次重大调整。市场对此反应迅速且剧烈，投资者担忧此举可能影响公司未来的增长前景与营收潜力。此次股价大幅波动，凸显了生物科技公司高度依赖研发管线进展的行业特性，任何关键项目的变动都可能引发资本市场的强烈震荡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111543060","title":"Agios Pharmaceuticals 镰状细胞病Tebapivat二期试验关键数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1111543060","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111543060?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:03","pubTimestamp":1780052603,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals公司宣布，其针对镰状细胞病的Tebapivat二期临床试验的关键顶线数据，预计将在2026年下半年出炉。这一时间点标志着该候选疗法研发进程中的一个重要里程碑，备受业界关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143667320","title":"Agios Pharmaceuticals公布Tebapivat治疗低危骨髓增生异常综合征二期B阶段试验结果未达预设阈值","url":"https://stock-news.laohu8.com/highlight/detail?id=1143667320","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143667320?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:02","pubTimestamp":1780052568,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc. 宣布，其药物Tebapivat用于治疗低危骨髓增生异常综合征（LR-MDS）的二期B阶段临床试验结果，未能达到预先设定的主要疗效终点阈值。该结果意味着该候选药物在此项关键研究中未展现出足以支持继续推进的统计学显著疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119640323","title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计增41.55%，关注mitapivat加速审批进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1119640323","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119640323?lang=zh_cn&edition=full","pubTime":"2026-04-23 03:29","pubTimestamp":1776886159,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc.将于2026年04月29日盘前发布最新季度财报，市场关注营收增速与研发催化的兑现节奏。收入构成显示，公司目前以“产品”作为主要收入来源，上季度该口径金额为5,402.80万美元，收入集中度较高。主要依据包括：对本季度营收同比增长41.55%的共识预期、调整后每股收益同比变动收窄至-0.95%、以及公司已就mitapivat在镰状细胞病适应症的加速批准路径与监管方进行沟通并推进补充申请准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计增41.55%，关注mitapivat加速审批进展","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126759159","title":"诺和诺德公布镰状细胞病药物后期数据 竞争对手Agios制药盘前重挫15.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126759159","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126759159?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:36","pubTimestamp":1776688619,"startTime":"0","endTime":"0","summary":"在竞争对手诺和诺德公布其镰状细胞病药物的后期临床试验数据后，Agios制药公司股价在盘前交易中暴跌15.5%。这一大幅下跌反映出市场对Agios核心产品面临潜在竞争威胁的担忧。\n诺和诺德披露的积极临床数据可能重塑镰状细胞病治疗领域的竞争格局，直接冲击Agios制药在该领域的市场地位。投资者迅速做出反应，大幅抛售Agios股票，导致其股价急剧下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141173806","title":"Agios与FDA召开Pre-SNDA会议后 推进米塔匹韦在镰状细胞病领域获美国加速批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1141173806","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141173806?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:03","pubTimestamp":1774955001,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals（纳斯达克代码：AGIO）宣布，在与美国食品药品监督管理局（FDA）成功举行新药上市申请前（Pre-SNDA）会议后，公司正积极推进其候选药物米塔匹韦（mitapivat）用于治疗镰状细胞病（SCD）的加速批准进程。\n此次关键会议明确了米塔匹韦在美国寻求加速批准的可行路径，标志着该药物在解决这一严重血液疾病方面迈出了重要一步。公司计划基于现有临床数据，尽快向FDA提交上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116513298","title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计增28.81%，机构观点偏审慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1116513298","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116513298?lang=zh_cn&edition=full","pubTime":"2026-02-05 11:29","pubTimestamp":1770262141,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc.预计在2026年02月12日发布最新季度财报，市场关注本季度营收与盈利承压的平衡，以及管线商业化进展对现金流的改善趋势。市场一致预期本季度Agios Pharmaceuticals, Inc.营收约为1,201.37万美元，同比增长28.81%；调整后每股收益预计为-1.95美元，同比降幅15.17%；息税前利润预计为-1.28亿美元，同比降幅17.77%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计增28.81%，机构观点偏审慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516630865","title":"Agios Pharmaceuticals, Inc.盘中异动 快速下挫5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516630865?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:45","pubTimestamp":1741013140,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时45分，Agios Pharmaceuticals, Inc.股票出现波动，股价急速下跌5.41%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。Agios Pharmaceuticals, Inc.公司简介：Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司，旨在为罕见疾病开发差异化药物，其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224541abe63813&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224541abe63813&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512207953","title":"Agios Pharmaceuticals, Inc.2024财年实现净利润6.74亿美元，同比增加291.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512207953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512207953?lang=zh_cn&edition=full","pubTime":"2025-02-17 00:01","pubTimestamp":1739721663,"startTime":"0","endTime":"0","summary":"2月17日，Agios Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为6.74亿美元，同比增加291.48%；其中营业收入为36.50百万美元，同比增加36.09%，每股基本收益为11.86美元。机构评级：截至2025年2月17日，当前有6家机构对Agios Pharmaceuticals, Inc.目标价做出预测，其中目标均价为56.67美元，其中最低目标价为45.00美元，最高目标价为74.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000114a2481c17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000114a2481c17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158994754","title":"Agios制药公司第四季度销售额1070万美元，高于预期的933万美元，净亏损9650万美元同比相比9590万美元，现金余额15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158994754","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158994754?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:42","pubTimestamp":1739446968,"startTime":"0","endTime":"0","summary":"Agios制药公司发布了第四季度财报，报告显示销售额为1070万美元，高于预期的933万美元。公司的净亏损为9650万美元，而去年同期为9590万美元。此外，公司目前的现金余额为15亿美元。以上内容来自Benzinga Earnings专栏，原文如下：N","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511546331","title":"Agios Pharmaceuticals(AGIO.US)：2024年Q4财报实现营收1070万美元，前值为710.3万美元，预期值为935万美元；每股收益为-1.94美元，前值为-1.72美元，预期值为-1.63美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511546331","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511546331?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:42","pubTimestamp":1739446935,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals(AGIO.US)：2024年Q4财报实现营收1070万美元，前值为710.3万美元，预期值为935万美元；每股收益为-1.94美元，前值为-1.72美元，预期值为-1.63美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13194248146637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agios.com","stockEarnings":[{"period":"1week","weight":-0.1744},{"period":"1month","weight":-0.1904},{"period":"3month","weight":0.0661},{"period":"6month","weight":0.094},{"period":"1year","weight":-0.1934},{"period":"ytd","weight":0.1029}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agios Pharmaceuticals, Inc.于2007年8月7日在特拉华州注册成立。该公司是一家生物制药公司，致力于通过细胞代谢领域的领导地位改变患者的生活，目标是为罕见病创造差异化药物，重点是经典血液学。","yearOnYearQuotes":[{"month":1,"riseRate":0.846154,"avgChangeRate":0.040392},{"month":2,"riseRate":0.692308,"avgChangeRate":0.060535},{"month":3,"riseRate":0.538462,"avgChangeRate":-0.001595},{"month":4,"riseRate":0.538462,"avgChangeRate":-0.007034},{"month":5,"riseRate":0.615385,"avgChangeRate":0.052079},{"month":6,"riseRate":0.692308,"avgChangeRate":0.062482},{"month":7,"riseRate":0.384615,"avgChangeRate":-0.026027},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.041451},{"month":9,"riseRate":0.538462,"avgChangeRate":0.042929},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.007074},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033339},{"month":12,"riseRate":0.384615,"avgChangeRate":-0.051358}],"exchange":"NASDAQ","name":"Agios Pharmaceuticals, Inc.","nameEN":"Agios Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agios Pharmaceuticals, Inc.(AGIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Agios Pharmaceuticals, Inc.(AGIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Agios Pharmaceuticals, Inc.,AGIO,Agios Pharmaceuticals, Inc.股票,Agios Pharmaceuticals, Inc.股票老虎,Agios Pharmaceuticals, Inc.股票老虎国际,Agios Pharmaceuticals, Inc.行情,Agios Pharmaceuticals, Inc.股票行情,Agios Pharmaceuticals, Inc.股价,Agios Pharmaceuticals, Inc.股市,Agios Pharmaceuticals, Inc.股票价格,Agios Pharmaceuticals, Inc.股票交易,Agios Pharmaceuticals, Inc.股票购买,Agios Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agios Pharmaceuticals, Inc.(AGIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Agios Pharmaceuticals, Inc.(AGIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}